Follicular Lymphoma (FL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Follicular Lymphoma (FL) Market Outlook

Thelansis’s “Follicular Lymphoma (FL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Follicular Lymphoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Follicular Lymphoma (FL) Overview

Follicular lymphoma, constituting 20-30% of all non-Hodgkin lymphomas, is the most prevalent subtype of low-grade (indolent) lymphoma. Its etiology remains unknown, ruling out infection as a causative factor and eliminating its potential for contagion. B-cell lymphoma, known as follicular lymphoma, is identified by tumor cells organized in a circular or clustered arrangement under microscopic examination. These anomalous follicles supplant the typical lymph node structure. Notably, over 90% of individuals with follicular lymphoma exhibit the CD20 protein on the surface of the malignant follicular cells, rendering them susceptible to certain treatment approaches. Prognosis and risk assessment for follicular lymphoma hinge on factors derived from the FLIP2 study, including Beta2 microglobulin exceeding the upper limit of normal, bone marrow involvement, hemoglobin levels below 12g/dL, the largest involved node's diameter exceeding 6 cm, and an age surpassing 60 years. The five-year progression-free survival rates based on these risk factors are as follows: Low risk (0 risk factors): 80%; Intermediate risk (1-2 risk factors): 51%; High risk (3-5 risk factors): 19%. The management of follicular lymphoma is contingent on the stage of the disease. Available treatment options encompass radiation therapy (RT), immunochemotherapy (Rituximab combined with chemotherapy), Bendamustine in conjunction with immunotherapy, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), immunochemotherapy combined with RT, CVP (cyclophosphamide, vincristine, and prednisolone), single-agent rituximab, and a strategy of monitoring until progression. The choice of treatment regimen is guided by the disease stage, the physician's recommendation, and the patient's preference.

• The incidence rate of new cases of follicular lymphoma in the United States amounts to 2.5 cases per 100,000 men and women annually.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: